MOBILE HEALTH APP TO MITIGATE THE METABOLIC EFFECTS OF ANDROGEN DEPRIVATION THERAPY: A RANDOMIZED PILOT TRIAL IN MEN NEWLY TREATED WITH ANDROGEN DEPRIVATION THERAPY
This research study seeks to develop and evaluate a mobile health app which aims to provide
patients who are about to initiate androgen deprivation therapy for prostate cancer with an
exercise program and better eating habits.
- All recruited participants must have owned a smartphone for >1 year
- Patients with prostate cancer aged between 40-75 years will be considered.
- No specific timeframe after prostate cancer diagnosis will be required for these
- No limitations regarding their disease characteristics will be imposed (e.g.
- Patients may or may not be currently receiving treatment Staff members will be
- Dana-Farber Cancer Institute Department of Medical Oncology,
- Brigham and Women's Hospital, Department of Surgery. Staff members aged between 40-75
years old will be considered. Phase 2
- Men diagnosed with prostate cancer presenting to DF/BWHCC
- About to initiate ADT for the first time will be considered.
- Age range 40-75-years
- The ability to walk 400 m
- Medical clearance from their primary physician
- English speaking
- Cognitively alert
- Ability to read or hear with or without contacts/glass and hearing aid
- Ownership of a smartphone for >1yr
- Men who have been under a rigorous structured exercise regime, such as individuals who
engage in more than 900 minutes of moderate physical activity per week in the last 6
months will not be considered
- Post-ADT treatment
- Planned systemic chemotherapy
- Planned treatment with abiraterone or enzalutamide
- Bone metastases
- Acute illness
- Any musculoskeletal, cardiovascular, or neurologic disorders that could inhibit or put
them at risk from exercising
- Subordinates to the PI